BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 ...

Spain-based drugmaker REIG JOFRE has signed a commercial agreement with LEO Pharma, a privately-held Danish firm specializing ...

Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

A new survey commissioned by Leo Pharma confirms there’s plenty of room in the market for its chronic hand eczema treatment Anzupgo, which is currently under review by the FDA. The survey ...

LEO Pharma delivered another year of strong progress in 2024, with both sales growth and adjusted EBITDA margin ahead of the initial outlook for the year, putting the company on track to meet its ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to distribute and market the monoclonal antibody, toripalimab, in Europe.

LEO Pharma will host a symposium, “Chronic Hand Eczema: A New Day Is at Hand,” at 7 p.m. ET on March 6 at the Hyatt Regency Orlando ahead of the American Academy of Dermatology (AAD ...

LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D ...

An Ipsos survey commissioned by LEO Pharma Inc. reveals dermatology providers believe there is a lack of awareness and understanding of chronic hand eczema as a condition separate from eczema ...